Functionality as a goal in the treatment of schizophrenia;La funcionalidad como objetivo en el tratamiento de la esquizofrenia

Actas Espanolas de Psiquiatria

Volumn 30, Issue 5, 2002, Pages 312-325

  Bousono Garcia M ^a  

^a UNIVERSIDAD DE OVIEDO   (Spain)

Author keywords

Functionality; Outcomes; Schizophrenia; Treatment

Indexed keywords

NEUROLEPTIC AGENT;

CLINICAL FEATURE; CLINICAL PRACTICE; COGNITION; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; HUMAN; MEDICAL ASSESSMENT; PSYCHIATRIC TREATMENT; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL STATUS; SYMPTOM; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; GOALS; HUMANS; NEUROPSYCHOLOGICAL TESTS; QUALITY OF LIFE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0036765074     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Gold JM, Harvey PD. Cognitive Deficits in Schizophrenia Psychiatric. Clinics of North America 1993;16 (2):295-312.
2. Rund BR. A Review of Longitudinal Studies of Cognitive Functions in Schizophrenia Patients. Schizophrenia Bulletin 1998;24(3):425-35.
3. Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effect of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophrenia Bull 1999;25:201-22.
4. Sharma T, Harvey P. Cognition in Schizophrenia. Impairments, importance, and treatment strategies. Oxford: Oxford University Press; 2000.
5. Sanjuán J. Neuropsicología de las esquizofrenias. Más datos más interrogantes. Archivos de Neurobiología 1998;61:257-60.
6. Pickup G, Frith C. Theory of mind impairments in schizophrenia: symptomatology, severity and specificity. Psychological Medicine 2001;31:207-20.
7. Muesser KT, Drake RE, Bond GR. Recent advances in psychiatric rehabilitation for patients with severe mental illness. Harvard Review of Psychiatry 1997;5:123-37.
8. Siris SG. Depression in Schizophrenia: Perspective in the era of «Atypical» antipsychotic agents. Am J Psychiatry 2000;157:1379-89.
9. Rifkin A, Qitkin E Klein DF. Akinesia: a poorly recognized drug-induced extrapiramidal behavioral disorder. Arch Gen Psychiatry 1975;32:672-4.
10. Rifkin A, Quitkin F, Kane JM, Klein DF. Are prophylactic antiparkinson drugs necessary? Arch Gen Psychiatry 1978;35:483-9.
11. Van Putten T, May PRA. «Akinetic depression» in schizophrenia. Arch Gen Psychiatry 1978;35:1101-7.
12. De Figueiredo JM. Depression and demoralization: phenomenologic differences and research perspectives. Comprehensive Psychiatry 1993;34:308-11.
13. Judd LL. Mood disorders in schizophrenia: epidemiology and comorbidity. Journal of clinical Psychiatry 1998;16:2-4.
14. Bottlender R, Straub A, Moller HJ. Prevalence and background factors of depression in first admitted schizophrenia patients. Acta Psychiatrica Scandinavica 2000;101:153-60.
15. Hafner H, Loffler W, Maurer K, et al. Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. Acta Psychiatrica Scandinavica 2000;100:105-18.
16. Mauri MC, Bitetto A, Fabiano L, Laini V, Steinhilber C, Fornier M, et al. Depressive symptoms and schizophrenic relapses: the effect of four neuroleptic drugs. Prog Neuropsychopharmacol Biol Psychiatry 1999;23:43-54.
17. Sands JR, Harrow M. Depression during the longitudinal course of schizophrenia. Schizophrenia Bulletin 1999;25:157-71.
18. Baynes D, Mulholland C, Cooper SJ, Montgomery RC, MacFlynn G, Lynch G, et al. Depressive symptoms in stable chronic schizophrenia. Schizophrenia Research 2000;45:47-56.
19. Mousaoui D, el Kadiri M, Agoub M, et al. Depression, suicidal ideation and schizophrenia. Encephale 1999;25 Spec No 3:9-11.
20. Zisook S, McAdams LA, Kuck J, Harris MJ, Bailey A, Patterson JL, et al. Depressive symptoms in schizophrenia. American Journal of Psychiatry 1999;156:1736-43.
21. Gutiérrez Rodríguez M, García Cabeza I, Sánchez Diaz EI, et al. Depressive experiences in schizophrenia. Arch Psiquiatr 2000;63(1):81-92.
22. Muller MJ, Wetzel H, Szegedi A, Benkert O. Three dimensions of depression in patients with acute psychotic disorders: a replication study. Comprehensive Psychiatry 1999;40:449-57.
23. Brevion G, Amador X, Smith M, et al. Depression, psychomotor retardation, negative symptoms and memory in schizophrenia. Neuropsychiatry Neuropsychol Behav Neurol 2000;13:177-83.
24. Siris SG. Depression in Schizophrenia: Perspective in the era of «Atypical» antipsychotic agents. Am J Psychiatry 2000;157:1379-89.
25. Joseph R. Frontal lobe psychopathology: mania, depression, confabulation, catatonia, perseveration, obsessive compulsions, and schizophrenia. Psychiatry 1999;62:138-72.
26. Heinz A. Anhedonia a general nosology surmounting correlate of a dysfunctional dopaminergic system? Nervenarzt 1999;70:391-8.
27. Anónimo. The prevalence of comorbid substance misuse and its influence on suicidal ideation among in-patients with schizophrenia. Acta Psychiatrica Scandinavica 2000;101(6):452-6.
28. Dollfus S, Rybeire JM, Petit M. Objective and subjective extrapyramidal side effects in schizophrenia: their relationship with negative and depressive symptoms. Psychopathology 2000.
29. Gervin M, Browne S, Garavan J, Roe M, Larkin C, O'Callaghan E. Dysphoric subjective response to neuroleptics in schizophrenia: relationship to extrapyramidal side effects and symptomatology. European Psychiatry 1999;14:405-9.
30. Moore O, Cassidy E, Carr A, O'Callaghan E. Unawareness of illness and its relationship with depression and self-deception in schizophrenia. Eur Psychiatry 1999;14:264-9.
31. Smith TE, Hull JW, Israel LM, Willson DF. Insight, symptoms, and neurocognition in schizophrenia and schizoaffective disorder. Schizophrenia Bulletin 2000;26(1):193-200.
32. Ventura J, Nuechterlein KH, Subotnik KL, Haresty JR Mintz J. Life events can trigger depressive exacerbation in the early course of schizophrenia. Journal of abnormal psychology 2000;109(1): 139-44.
33. Hoffman H, Kupper Z, Kunz B. Hopelessness and its impact on rehabilitation outcome in schizophrenia - an exploratory study. Schizophrenia Research 2000;43:147-58.
34. Olfson M, Mechanic D, Boyer CA, Hansell S, Walkup J, Weiden PJ. Assessing clinical predictions of early rehospitalization in schizophrenia. Journal of Nervous and Mental Diseases 1999;187:721-9.
35. Meltzer HY. Suicide and schizophrenia: clozapine and the InterSePT Study. International Clozaril/Leponex Suicide Prevention Trial. Journal of Clinical Psychiatry 1999;60 Suppl 12:47-50.
36. Osby V, Correia N, Brandt L, et al. Mortality and causes of death in Stockholm County, Sweden. Schizophrenia Research 2000;45:21-8.
37. Harvaky-Friedman JM, Restifo K, Malaspina D, et al. Suicidal behavior in schizophrenia: characteristics of individuals who had and had not attempted suicide. American Journal of Psychiatry 1999;156:1276-8.
38. Radomsky Ed, Haas GL, Mann JJ, Sweeney JA. Suicidal behavior in patients with schizophrenia and other psychotic disorders. American Journal of Psychiatry 1999;156:1590-5.
39. Sands JR, Harrow M. Depression during the longitudinal course of schizophrenia. Schizophrenia Bulletin 1999;25:157-71.
40. Saarinen PI, Lehtonen J, Lonnqvist J. Suicide risk in schizophrenia: an analysis of 17 consecutive suicides. Schizophrenia Bulletin 1999;25:533-42.
41. Fenton WS. Depression, suicide, and suicide prevention in schizophrenia. Suicide and life threatening behavior 2000;30:34-9.
42. Levinson DF, Umapathy C, Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms. American Journal of Psychiatry 1999;156:1138-48.
43. Murray CJL, López AD. The Global Burden of Disease. Geneva: World Health Organization; 1996. p. 270.
44. Hansen TE, Casey DE, Hoffman WF. Neuroleptic Intolerance. Schizophrenia Bulletin 1997;23(4):567-82.
45. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull 1993;19:609-18.
46. Medalia A, Gold J, Merriam A. The effects of neuroleptics on neurospsychological test results of schizophrenics. Arch Clin Neuropsychol 1988;3:249-71.
47. Franz M, Lis S, Pluddemann Gallhofer B. Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. British Journal of Psychiatry 1997;170:422-5.
48. Baldwin DS. Psychotropic drugs and sexual dysfunction. International Review of Psychiatry 1995;7:261-73.
49. Montejo AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction. Fluoxetine, Paroxetine, Sertraline and Fluvoxamine in a prospective, multi-center and descriptive clinical study of 344 patients. Journal of Sex and Marital Therapy 1997;23(3):176-84.
50. Bousoño M, Bascarán MT, Sáiz P, et al. La disfunción sexual como pieza clave en los tratamientos a largo plazo. Psiquiatría Biológica 1999;6 Suppl 1:14-20.
51. Merino MJ, García M. Antidepresivos y disfunciones sexuales: biología, clasificación y tratamiento. Rev Asoc Esp Neuropsiq 1995;54:431-42.
52. Lukoff D, Gioia-Hasick D, Sullivan G, Golden JS, Nuechterlein KH. Sex education and rehabilitation with schizophrenic male outpatients. Schizophr Bull 1986;12(4):669-77.
53. Chen EY, Lee AS. Neuroleptic induced priapism, hepatotoxicity and subsequent impotence in a patient with depressive psychosis. Br J Psychiatry 1990;157:759-62.
54. Griffith SR, Zil JS. Priapism in a patient receiving antipsychotic therapy. Psychosomatics 1984;25(8):629-31.
55. Mitchell JE, Popkin MK. Antipsychotic drug therapy and sexual dysfunction in men. Am J Psychiatry 1982;139(5):633-7.
56. Nestoros JN, Lehmann HE, Ban TA. Sexual behavior of the male schizophrenic: the impact of illness and medications. Arch Sex Behav 1981;10(5):421-42.
57. Jacobs P, Bobek SC. Sexual needs of the schizophrenic client. Perspect Psychiatr Care 1991;27(1): 15-20.
58. Leff. Aiding resocialization of the chronic psychotic patient. Int Clin Psychopharmacol 1997;12 Suppl 4:S19-24.
59. Dikson RA, Glaser W. Development of a scale to assess sexual functioning. En: Antipsychotic Medication and Sexuality. Program and abstract from the 153 Annual American Association Meeting, May 13-18, 2000. Chicago. Abstract. S35.
60. Montejo AL, et al. Antipsicóticos y Afectación de la Respuesta Sexual. En: Bobes J, Dexeus S, Gibert J, editores. Psicofármacos y Función Sexual. Madrid: Ediciones Díaz de Santos; 1999. p. 111-32.
61. Kraepelin E. Dementia praecox and paraphrenia. New York: Robert editorial Kreiger (original work published in 1919). 1971.
62. Bleuler E. Dementia praecox or the group of schizophrenias. New York: International Universities Press (original work published in 1911). 1950.
63. Johnstone EC, MacMillan JF, Frith CD, Benn DK, Crow TJ. Further investigation of the predictors of outcome following first schizophrenic episodes. British Journal of Psychiatry 1990;157:182-9.
64. Jonsson H, Nyman AK. Predicting long-term outcome in schizophrenia. Acta Psychiatric Scandinavica 1991;83:342-6.
65. Sullivan G, Marder SR, Liberman RP, Donahoe CP, Mintz J. Social skills and relapse history in outpatient schizophrenics. Psychiatry 1990;53:340-5.
66. Bailer J, Braüer W, Rey ER. Premorbid adjustment as predictor of Outcome in schizophrenia: Results of a prospective study. Acta Psychiatric Scandinavica 1996;93:368-77.
67. Penn DL, Mueser KT. Research update on the psychosocial treatment of schizophrenia. Am J Psychiatry 1996;153:607-17.
68. McGorry, Curry C, Elkins K. Psychosocial interventions in mental health disorders: developing evidence-based practice. Current Opinion in Psychiatry 1997;10:173-7.
69. Bustillo J, Lauriello J, Horan W, Keith S. The psychosocial treatment of schizophrenia: an update. Am J Psychiatry 2001;158:163-75.
70. Lehman AF, Carpenter WT Jr, Goldman HH, Steinwachs DM. Treatment outcomes in schizophrenia: implications for practice, policy, and research. Schizophr Bull 1995;21:669-75.
71. Fenton WS, Schooler NR. Evidence-based psychosocial treatment for schizophrenia. Schizophr Bull 2000;26:1-3.